Cencora (COR) Baird's 2024 Global Healthcare Conference summary

Guidance updates and financial outlook

• Raised fiscal 2024 EPS guidance to $13.60–$13.70 per share, reflecting continued strong performance.

• Initial fiscal 2025 guidance set at the lower end of long-term ranges: ~5% adjusted operating income growth and ~8% adjusted EPS growth.

• COVID-related income normalization and potential loss of an oncology customer cited as primary and secondary factors for 2025 guidance.

• Three-year contract extension with second-largest customer, Evernorth/Express Scripts, through 2029.

• Long-term guidance remains unchanged, emphasizing confidence in achieving stated targets.

Customer relationships and strategic partnerships

• Walgreens remains the largest customer, with high operational integration and contracts in place through 2029 (U.S.) and 2031 (U.K.).

• Walgreens' share sales have been managed through repurchases, maintaining a strong partnership.

• Larger customers are acknowledged as lower-margin contributors.

• Emphasis on mutually beneficial, win-win opportunities in customer negotiations.

• Evernorth/Express Scripts contract extended, reinforcing stability in key accounts.

Market trends and sector dynamics

• Revenue growth in the sector expected to normalize to mid-single digits, with margin and operating income as primary focus.

• Biosimilar adoption in Part D may reduce revenue but has minimal profit impact; Part B biosimilars present margin opportunities.

• GLP-1s are significant for revenue but remain minimally profitable; long-term margin improvement expected with increased supply and competition.

• Specialty markets, particularly oncology and urology, are key growth areas.

• Industry-wide factors like insulin price cuts, biosimilar launches, and GLP-1 growth create revenue line volatility.